Перейти
на сайт журнала "Врач" |
Перейти на сайт журнала "Медицинская сестра"
|
Перейти на сайт журнала "Фармация"
|
Перейти на сайт журнала "Молекулярная медицина"
|
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
|
Журнал включен в российские и международные библиотечные и реферативные базы данных
ВАК (Россия)
|
РИНЦ (Россия)
|
Эко-Вектор (Россия)
|
SEARCHING FOR SELECTIVE INHIBITORS OF MATRIX METALLOPROTEINASE TYPE 2 IN A SERIES OF BENZOYLAMINO (PHENYLSULFONYL)-SUBSTITUTED CYCLIC AMINO ACID DERIVATIVES
DOI: https://doi.org/10.29296/25877313-2020-11-04
Issue:
11
Year:
2020
Relevance. Matrix metalloproteinases type 2 and 9 (MMP-2, MMP-9) initiate collagen degradation of the extracellular myocardial matrix in acute infarction which is accompanied by their release into the systemic circulation. MMP inhibitors are known to reduce post-infarction remodeling of the left ventricle of the heart. Effective cardiotropic drugs can be created based on them. Aim. Searching for selective matrix metalloproteinase type 2 inhibitors among benzoylamino(phenylsulfonyl)-substituted cyclic amino acid derivatives. Material and methods. Potential inhibitors were designed and synthesized earlier in the Zakusov Institute of Pharmacology. Inhibition constants were determined fluorimetrically using a substrate Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 and recombinant, active human MMP-2 and MMP-9. Effect of the most active inhibitors on the level of MMP-2 in the rat blood plasma with acute myocardial infarction (AMI) was determined in outbred male rats. AMI was reproduced by ligation of the coronary artery. The level of MMP-2 was determined by enzyme immunoassay. Results. It was shown that 1-{4-[(4-chlorobenzoyl)amino]phenyl}sulfonyl-L-proline (code AL-828) and 1-{4-[(2-chlorobenzoyl)-amino]phenyl}sulfonyl-L-proline (code ML-269) are selective MMP-2 inhibitors with inhibition constants 45±8,5 µМ and 82,5±17,2 µМ, respectively. Compounds AL-828 and ML-269 reduce the level of MMP-2 in the blood plasma of rats with AMI in the doses of 30 mg/kg/day per os by 9% and 19% with p=0.08 and p=0.007, respectively, and, at least, are not inferior in their activity to the comparison drug doxycycline (40 mg/kg/day). Conclusion. Selective inhibitors of MMP-2, compounds ML-269 and AL-828, which can become the basis for the creation of cardioprotective drugs that prevent pathological post-infarction remodeling of the left ventricle of the heart were revealed.
Keywords:
1-{4-[(2-chlorobenzoyl)amino]phenyl}sulfonyl-L-proline
1-{4-[(4-chlorobenzoyl)amino] phenyl}sulfonyl-L-proline
AL-828
ML-869
MMP-2
inhibitor
acute myocardial ischemia
References:
- Vsemirnaja organizacija zdravoohranenija: [sajt]. URL: https://www.who.int/ru/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (data obrashhenija 28.02.2020).
- Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 2007; 87: 1285 1342.
- Simova J., Skvor J., Slovak D., et al. Serum Levels of Matrix Metalloproteinases 2 and 9 in Patients with Acute Myocardial Infarction. Folia Biol. 2013; 59: 181–187.
- Hori M., Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc. Res. 2009; 81(3): 457–464.
- Creemers E., Cleutjens J., Smits J., et al. Matrix Metallo-proteinase Inhibition After Myocardial Infarction: A New Approach to Prevent Heart Failure? Circ Res. 2001; 89: 201–210.
- Laronha H., Carpinteiro I., Portugal J., et al. Challenges in Matrix Metalloproteinases Inhibition. Biomolecules. 2020; 10 (5); 717.
- Grigorkevich O.S., Mokrov G.V., Djabina A.S. i dr. Dizajn, sintez i farmakologicheskaja aktivnost' novogo ingibitora matriksnoj metalloproteinazy-9. Himiko-farmacevticheskij zhurnal. 2018; 52(1): 8–14.
- Seredenin S.B., Mokrov G.V., Kryzhanovskij S.A., Lihosherstov A.M. i dr. Ingibitory cink-zavisimyh metalloproteinaz (MMP-2 i MMP-9) v rjadu benzoilamino(fenilsul'fonil)-zameshhennyh ciklicheskih aminokislot kak potencial'nye lekarstvennye sredstva, prepjatstvujushhie postinfarktnomu remodelirovaniju levogo zheludochka serdca. Patent RF № 2646752. 2016.
- Faust A. Waschkau B., Waldeck J., et al. Synthesis and Evaluation of a Novel Fluorescent Photoprobe for Imaging Matrix Metalloproteinases. Bioconjugate Chem. 2008; 19: 1001–1008.
- Cerisano G., Buonamici P., Gori A.M., et al. Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial. Int. J. Cardiol. 2015; 197: 147–153.